ArticleDiscover oncology2025
Survival outcomes and prognostic factors of breast cancer spinal metastases: a retrospective study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case of salvageSurgical neurology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo investigate survival-related factors in patients with breast cancer spinal metastases (BCSM) within the context of multidisciplinary treatment.
methodsA retrospective cohort of 78 cases from July 2010 to December 2021 was recruited. These patients underwent surgery-based multidisciplinary treatment. Collected data included demographics, pathologies, symptoms, surgery-related data, adjuvant therapies, postoperative events, and survival data. The primary outcome was overall survival (OS). Kaplan-Meier survival curves were plotted. Univariate analysis employed the log-rank test, and post-hoc multivariate analysis utilized the Cox regression model.
resultsThe mean age was 50.9 years. 72 cases (92.3%) reported locoregional pain, and 30 cases (38.5%) presented with neurological dysfunction. The primary pathological subtype was invasive ductal carcinoma (83.3%). SURGICAL PROCEDURES: total en-bloc spondylectomy (6.4%), debulking surgery (61.5%), palliative surgery (32.1%). Postoperatively, both pain and neurological function significantly improved (P < 0.05). Radiotherapy, endocrine therapy, chemotherapy/targeted therapy were given to 56.4%, 60.3%, 61.5% patients, respectively. The estimated OS was 50.0 months. Tomita's scores (P = 0.355) and Tokuhashi's scores (P = 0.461) showed no significant OS association. Univariate analysis indicated that preoperative neurological dysfunction (P = 0.003), postoperative neurological dysfunction (P = 0.051), adjuvant endocrine therapy (P = 0.025), and hormone receptor expression status (P = 0.009) were associated with patient survival. Multivariate analysis identified endocrine therapy as an independent protective factor for prognosis (aHR = 0.070, 95% CI 0.007-0.727, P = 0.026).
conclusionsPatients with BCSM have experienced prolonged survival. Neurological status, adjuvant anti-drugs, and expression of hormone receptors played crucial roles in predicting survival. Conventional prognostic systems may require modification to incorporate these factors. However, this study has limitations inherent to its retrospective design, single-center cohort, and relatively small sample size, which may affect generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.